William C Olson

US Patent:

6710173, Mar 23, 2004

Filed:

Jun 23, 2000

Appl. No.:

09/602864

Inventors:

James M. Binley - Brooklyn NY
Norbert Schuelke - New City NY
William C. Olson - Ossining NY
Paul J. Maddon - Scarsdale NY
John P. Moore - New York NY

Assignee:

Progenics Pharmaceuticals, Inc. - Tarrytown NY
Aaron Diamond AIDS Research Centre (ADARC) - New York NY

International Classification:

C07H 2104

US Classification:

536 2372, 4241881, 4242081

Abstract:

This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention also provides a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention further provides methods of treating HIV-1 infection.

US Patent:

7022324, Apr 4, 2006

Filed:

Dec 21, 2001

Appl. No.:

10/032162

Inventors:

James M. Binley - Brooklyn NY, US
Norbert Schuelke - New City NY, US
William C. Olson - Ossining NY, US
Paul J. Maddon - Scarsdale NY, US
John P. Moore - New York NY, US

Assignee:

Progenics Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

A61K 39/21

US Classification:

4241881, 4242081

Abstract:

This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention also provides a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention further provides methods of treating HIV-1 infection.

US Patent:

7479553, Jan 20, 2009

Filed:

Feb 18, 2004

Appl. No.:

10/780993

Inventors:

James M. Binley - Brooklyn NY, US
Norbert Schuelke - New City NY, US
William C. Olson - Ossining NY, US
Paul J. Maddon - Scarsdale NY, US
John P. Moore - New York NY, US

Assignee:

Progenics Pharmaceuticals, Inc. - Tarrytown NY
Aaron Diamond AIDS Research Centre (ADARC) - New York NY

International Classification:

C07H 21/04
A61K 39/21

US Classification:

536 2372, 4242081

Abstract:

This invention provides a DNA which upon transcription produces an RNA encoding a modified HIV-1 gp140 polypeptide, which polypeptide upon cleavage produces a modified gp120 and a modified ectodomain of gp41 which together form a complex exhibiting enhanced binding to HIV-1 neutralizing antibodies and reduced binding to HIV-1 non-neutralizing antibodies, wherein the modifications comprise an A492C mutation in gp120 and a T596C mutation in gp41, said mutations being numbered by reference to the HIV-1 isolate JR-FL, and resulting in a disulfide bond between gp120 and ectodomain gp41 which stabilizes the otherwise non-covalent gp120-gp41 interaction.

US Patent:

7592014, Sep 22, 2009

Filed:

Oct 28, 2005

Appl. No.:

11/261390

Inventors:

James M. Binley - Brooklyn NY, US
Norbert Schuelke - New City NY, US
William C. Olson - Ossining NY, US
Paul J. Maddon - Scarsdale NY, US
John P. Moore - New York NY, US

Assignee:

Progenics Pharmaceuticals Inc. - Tarrytown NY
Aaron Diamond Aids Research Centre (ADARC) - New York NY

International Classification:

A61K 39/21

US Classification:

4242081

Abstract:

This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention also provides a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention further provides methods of treating HIV-1 infection.

US Patent:

20050089526, Apr 28, 2005

Filed:

Sep 6, 2002

Appl. No.:

10/489040

Inventors:

John Moore - New York NY, US
James Binley - San Diego CA, US
Min Lu - New York NY, US
William Olson - New York NY, US
Norbert Schulke - New City NY, US
Jason Gardner - Ardsley NY, US
Paul Maddon - Scarsdale NY, US
Rogier Sanders - Amsterdam, NL

International Classification:

A61K039/21
C07K014/16

US Classification:

424188100, 530395000

Abstract:

This invention provides stable HIV-1 pre-fusion envelope glycoprotein trimeric complexes. This invention also provides related polypeptides and compositions comprising pharmaceutically acceptable particles and the trimeric complexes operably affixed thereto. This invention further provides related nucleic acids, vectors, host cells, compositions, production methods, and prophylactic and therapeutic methods.

US Patent:

20210340267, Nov 4, 2021

Filed:

Mar 5, 2021

Appl. No.:

17/193586

Inventors:

- TARRYTOWN NY, US
Drew Dudgeon - Union NJ, US
Yu Huang - Ossining NY, US
Rosalynn Molden - Fox Island WA, US
William Olson - Yorktown Heights NY, US
Matthew Sleeman - Yorktown Heights NY, US
Dimitris Skokos - New York NY, US
Bei Wang - Hastings-on-Hudson NY, US

International Classification:

C07K 16/28
A61P 35/00
A61K 45/06
A61K 39/395

Abstract:

Provided herein are antibodies, and antigen-binding fragments thereof that specifically bind glucocorticoid-induced tumor necrosis factor receptor (GITR), compositions comprising the antibodies or antigen-binding fragments thereof, and methods of using the same, including, e.g., methods of treatment using the same.

US Patent:

20210260208, Aug 26, 2021

Filed:

Dec 20, 2019

Appl. No.:

16/724164

Inventors:

- Tarrytown NY, US
Marcus KELLY - New York NY, US
William OLSON - Yorktown Heights NY, US

International Classification:

A61K 47/68
A61K 31/454
A61K 47/54
A61K 47/65

Abstract:

Provided herein are compounds, compositions, and methods for the treatment of diseases and disorders associated with cancer, including tubulysins and protein (e.g., antibody) drug conjugates thereof.